[go: up one dir, main page]

PE20170697A1 - Indazoles sustituidos con benzilo como inhibidores de bub1 - Google Patents

Indazoles sustituidos con benzilo como inhibidores de bub1

Info

Publication number
PE20170697A1
PE20170697A1 PE2017000480A PE2017000480A PE20170697A1 PE 20170697 A1 PE20170697 A1 PE 20170697A1 PE 2017000480 A PE2017000480 A PE 2017000480A PE 2017000480 A PE2017000480 A PE 2017000480A PE 20170697 A1 PE20170697 A1 PE 20170697A1
Authority
PE
Peru
Prior art keywords
benzyl
indazol
ethanol
amino
alkyl
Prior art date
Application number
PE2017000480A
Other languages
English (en)
Inventor
Anne Mengel
Hans-Georg Lerchen
Manfred Mowes
Thomas Muller
Lars Barfacker
Marion Hitchcock
Arwed Cleve
Joachim Kuhnke
Hans Briem
Gerhard Siemeister
Wilhelm Bone
Amaury Ernesto Fernandez-Montalvan
Jens Schroder
Ursula Monning
Simon Holton
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20170697A1 publication Critical patent/PE20170697A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se refiere a compuestos de formula I, en donde: V, W, Y y Z son CH o CR2; R1 es alquilo C1-C6, haloalquilo C1-C6, cicloalquilo C3-C6, entre otros; R2 es halogeno, alquilo C1-C3, haloalquilo C1-C3, entre otros; R3 es hidroxialquilo C2-C6 o R4; R4 es (alquilo C2-C6)-OC(=O)-C(H)(R5)-N(H)C(=O)-C(H)(R7)-NH2. Son compuestos preferidos: 2-2-{4-[(3-{4-[(3-cloropiridin-4-il)amino]-5-metoxipirimidin-2-il}-1H-indazol-1-il)metil]-3,5-difluorofenoxi}etanol, 2-{3,5-difluoro-4-[(3-{5-metoxi-4-[(2-metilpiridin-4-il)amino]pirimidin-2-il}-1H-indazol-1-il)metil]fenoxi}etanol, 2-{3,5-difluoro-4-[(3-{5-metoxi-4-[(3-metoxipiridin-4-il)amino]pirimidin-2-il}-1H-indazol-1-il)metil]fenoxi}etanol, entre otros. Dichos compuestos inhiben la quinasa Bub1 y son utiles en el tratamiento de trastornos proliferativos
PE2017000480A 2014-09-19 2015-09-17 Indazoles sustituidos con benzilo como inhibidores de bub1 PE20170697A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185604 2014-09-19
EP15176903 2015-07-15
PCT/EP2015/071340 WO2016042084A1 (en) 2014-09-19 2015-09-17 Benzyl substituted indazoles as bub1 inhibitors

Publications (1)

Publication Number Publication Date
PE20170697A1 true PE20170697A1 (es) 2017-06-24

Family

ID=54140475

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000480A PE20170697A1 (es) 2014-09-19 2015-09-17 Indazoles sustituidos con benzilo como inhibidores de bub1

Country Status (27)

Country Link
US (1) US10350206B2 (es)
EP (1) EP3194379A1 (es)
JP (1) JP6664385B2 (es)
KR (1) KR20170049604A (es)
CN (1) CN107001331A (es)
AP (1) AP2017009803A0 (es)
AU (1) AU2015316796A1 (es)
BR (1) BR112017005444A2 (es)
CA (1) CA2961589A1 (es)
CL (1) CL2017000654A1 (es)
CO (1) CO2017002532A2 (es)
CR (1) CR20170100A (es)
CU (1) CU20170029A7 (es)
DO (1) DOP2017000078A (es)
EA (1) EA032401B1 (es)
EC (1) ECSP17016797A (es)
IL (1) IL251071A0 (es)
MA (1) MA39484A (es)
MX (1) MX2017003664A (es)
NI (1) NI201700034A (es)
PE (1) PE20170697A1 (es)
PH (1) PH12017500509A1 (es)
SG (1) SG11201702082VA (es)
TN (1) TN2017000092A1 (es)
TW (1) TW201615636A (es)
UY (1) UY36311A (es)
WO (1) WO2016042084A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
CN105408324A (zh) 2013-06-21 2016-03-16 拜耳制药股份公司 取代的苄基吡唑
HK1223098A1 (zh) 2013-06-21 2017-07-21 Bayer Pharma Aktiengesellschaft 杂芳基取代的吡唑
CN105764893A (zh) 2013-10-30 2016-07-13 拜耳制药股份公司 杂芳基取代的吡唑
UA122121C2 (uk) 2014-02-06 2020-09-25 Хептерс Терап'Ютікс Лімітед Біциклічні азотовмісні сполуки як агоністи мускаринового м1 рецептора i/або м4 рецептора
ES2708211T3 (es) 2014-06-17 2019-04-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
TN2017000092A1 (en) 2014-09-19 2018-07-04 Bayer Pharma AG Benzyl substituted indazoles as bub1 inhibitors.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
CN108727340B (zh) 2017-04-11 2020-12-29 广东东阳光药业有限公司 氟取代的吲唑类化合物及其用途
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5470862A (en) 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
CA2268394C (en) 1996-10-14 2008-03-25 Bayer Aktiengesellschaft New heterocyclylmethyl-substituted pyrazol derivates
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
US7569592B2 (en) 2001-12-18 2009-08-04 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
CN1694708A (zh) 2002-09-10 2005-11-09 西奥斯股份有限公司 TGFβ的抑制剂
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
WO2007038613A2 (en) 2005-09-26 2007-04-05 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
CA2553513A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
BRPI0812361A2 (pt) 2007-05-18 2015-02-03 Bayer Schering Pharma Ag Derivados de pirazol heteroaril-substituídos úteis parao tratamento de distúrbios e doenças hiperproliferativos associados à angiogênese
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
ES2630026T3 (es) 2008-12-18 2017-08-17 Nerviano Medical Sciences S.R.L. Derivados indazólicos sustituidos activos como inhibidores de cinasa
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
EA031632B1 (ru) 2009-11-27 2019-01-31 Адверио Фарма Гмбх СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ{4,6-ДИАМИНО-2-[1-(2-ФТОРБЕНЗИЛ)-1H-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ]ПИРИМИДИН-5-ИЛ}МЕТИЛКАРБАМАТА
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
KR101955691B1 (ko) 2010-03-30 2019-03-07 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
CN107021951B (zh) 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC刺激物
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
CN104125957B (zh) 2011-12-21 2016-05-25 拜耳知识产权有限责任公司 取代的苄基吡唑
EP3112363A1 (en) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension
EP2847180B1 (en) 2012-05-11 2017-01-04 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
WO2014047325A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014047662A2 (en) 2012-09-24 2014-03-27 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
CN105164116A (zh) 2013-03-21 2015-12-16 拜耳制药股份公司 杂芳基取代的吲唑
WO2014147144A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
EP2976336A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
CN105408324A (zh) 2013-06-21 2016-03-16 拜耳制药股份公司 取代的苄基吡唑
EP3010911A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
HK1223098A1 (zh) 2013-06-21 2017-07-21 Bayer Pharma Aktiengesellschaft 杂芳基取代的吡唑
HK1222852A1 (zh) 2013-06-21 2017-07-14 Bayer Pharma Aktiengesellschaft 二氨基杂芳基取代的吡唑
CN105452236A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 取代的苄基吡唑
CN105764893A (zh) 2013-10-30 2016-07-13 拜耳制药股份公司 杂芳基取代的吡唑
JP2017535514A (ja) 2014-09-19 2017-11-30 バイエル ファーマ アクチエンゲゼルシャフト Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類
TN2017000092A1 (en) 2014-09-19 2018-07-04 Bayer Pharma AG Benzyl substituted indazoles as bub1 inhibitors.
CN107074825A (zh) 2014-09-19 2017-08-18 拜耳制药股份公司 作为bub1激酶抑制剂的苄基取代的吲唑类化合物
PT3194376T (pt) 2014-09-19 2019-02-04 Forma Therapeutics Inc Derivados da piridin-2(1h)-ona-quinolinona como inibidores da isocitrato-desidrogenase mutante
US9938260B2 (en) 2014-09-19 2018-04-10 Glaxosmithkline Intellectual Property Development Limited Soluble guanylate cyclase activators and their use
CN106659791A (zh) 2014-09-19 2017-05-10 雀巢产品技术援助有限公司 用α‑淀粉酶抑制剂为伴侣动物治疗癌症
CA2961570A1 (en) 2014-09-19 2016-03-24 Lars Barfacker Benzyl substituted indazoles
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors

Also Published As

Publication number Publication date
NI201700034A (es) 2017-06-16
JP2017530962A (ja) 2017-10-19
AU2015316796A1 (en) 2017-03-30
CA2961589A1 (en) 2016-03-24
CN107001331A (zh) 2017-08-01
TW201615636A (zh) 2016-05-01
PH12017500509A1 (en) 2017-08-30
IL251071A0 (en) 2017-04-30
EA201790649A1 (ru) 2017-09-29
CO2017002532A2 (es) 2017-07-11
BR112017005444A2 (pt) 2018-04-24
MX2017003664A (es) 2017-07-13
TN2017000092A1 (en) 2018-07-04
KR20170049604A (ko) 2017-05-10
CL2017000654A1 (es) 2017-12-11
EP3194379A1 (en) 2017-07-26
US20170273980A1 (en) 2017-09-28
UY36311A (es) 2016-04-29
JP6664385B2 (ja) 2020-03-13
SG11201702082VA (en) 2017-04-27
ECSP17016797A (es) 2017-05-31
CR20170100A (es) 2017-04-24
DOP2017000078A (es) 2017-06-30
AP2017009803A0 (en) 2017-03-31
MA39484A (fr) 2016-03-24
US10350206B2 (en) 2019-07-16
WO2016042084A1 (en) 2016-03-24
CU20170029A7 (es) 2017-08-08
EA032401B1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
PE20170697A1 (es) Indazoles sustituidos con benzilo como inhibidores de bub1
MX2022009998A (es) Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida.
CY1123443T1 (el) Οξεα καρβαμοϋλοξυμεθυλ-τριαζολ-κυκλοεξυλιου ως ανταγωνιστες lpa
MX384087B (es) Piperidinas como inhibidores de menina.
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
PE20161443A1 (es) Compuestos
ZA202101788B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
PE20170143A1 (es) Benzimidazol-2-aminas como inhibidores de midh1
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2022000376A (es) Aminopirimidinas como inhibidores de alk.
EA201790715A1 (ru) Новые соединения
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
PE20170939A1 (es) Pirimidinonas como inhibidores del factor xia
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20170662A1 (es) Compuestos de aminopiridiloxipirazol
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
MX393838B (es) Uso de compuestos heterociclicos para controlar nematodos.
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона